Skip to main content
Optipharm.CO.,LTD logo

Optipharm.CO.,LTD — Investor Relations & Filings

Ticker · 153710 ISIN · KR7153710009 KO Professional, scientific and technical activities
Open in API
Filings indexed 177 across all filing types
Latest filing 2020-09-14 Director's Dealing
Country KR South Korea
Listing KO 153710

About Optipharm.CO.,LTD

https://www.optipharm.co.kr

Optipharm is a biomedical company specializing in animal health solutions and advanced biotherapeutics. The company's core activities encompass animal disease diagnosis, the development and sale of veterinary pharmaceuticals, and the creation of bacteriophage-based treatments. A key focus is on preventative medicine, including the research and development of Virus-Like Particle (VLP) vaccines and a nanoparticle-based vaccine for Foot-and-Mouth Disease. In the biomedical sector, Optipharm is advancing xenotransplantation through its 'Medipig' platform for developing xenogeneic organs and tissues. The company also produces transgenic animal models for research and develops cell therapy products using animal stem cells, with a long-term strategy to transition its innovations to human medicine.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form used by executives and major shareholders to report changes in their shareholdings, commonly referred to as 'Director's Dealing' or 'Insider Trading' reports in international financial contexts. The content details the reporting person (Kim Hyun-il), the company (Optipharm), and the specific change in share ownership due to the exercise of stock options.
2020-09-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used by company insiders (directors/executives) to disclose their personal share transactions or changes in ownership. This falls under the 'Director's Dealing' category.
2020-09-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a standard Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This document is a mandatory disclosure filed by company insiders (directors/executives) to report changes in their personal shareholdings, which corresponds to the 'Director's Dealing' category in the provided schema.
2020-09-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service and Korea Exchange. It details the share ownership and changes in holdings (specifically a stock option exercise) by an executive (CFO) of Optipharm. This type of filing is a standard regulatory disclosure for insider trading/ownership changes, which falls under the 'Director's Dealing' category.
2020-09-14 Korean
기타경영사항(특허권취득)(자율공시)(신규한 바이러스 유사입자, 이를 포함하는 돼지 써코바이러스 3에 의한 질환에 대한 백신 조성물, 및 이의 제조 방법)
Regulatory Filings Classification · 1% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent by Optipharm. It details the patent name, content, and utilization plan. Since it is a regulatory announcement regarding a specific corporate event (patent acquisition) that does not fit into financial reporting, M&A, or other specific categories, it falls under the general regulatory filing category.
2020-09-03 Korean
반기보고서 (2020.06)
Interim / Quarterly Report Classification · 1% confidence The document is a '반기보고서' (Semi-annual Report) for the company 'Optipharm' covering the period from January 1, 2020, to June 30, 2020. It contains detailed financial information, business descriptions, and management disclosures, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2020
2020-08-14 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.